Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995
Buy Report Download FREE Resources

Published: December 08, 2025 Report Code: GDHCOA061-ST

Select Item

Insomnia market opportunity analysis: explore 7MM forecasts, pipeline products, treatment trends, market growth, competitive intelligence, and opportunities through 2032.

Understand the Future of the Insomnia Therapeutics Market

The insomnia therapeutics market continues to evolve as treatment innovation, unmet patient needs, and changing prescribing patterns reshape the competitive landscape.

This report provides a comprehensive analysis of the insomnia market across the 7MM, supported by an Excel-based forecast model covering the period from 2022 to 2032.

Z-drugs remain the most common first-line treatment across the US and 5EU markets, while the current pipeline remains limited but diverse, featuring products with varying mechanisms of action.

The report highlights five pipeline products currently in Phase II and III stages of development, alongside detailed analysis of market dynamics, treatment usage, and competitive positioning.

Report Value Proposition – Why This Matters for You

This report is designed to support pharmaceutical companies, investors, and strategy teams evaluating opportunities within the insomnia therapeutics space.

You can use it to:

  • Analyze insomnia market forecasts across the 7MM through 2032
  • Evaluate emerging pipeline products and mechanisms of action
  • Understand treatment usage patterns and therapy costs
  • Benchmark competitors and assess market positioning
  • Identify unmet needs and future commercial opportunities
  • Support licensing, investment, and commercialization strategies

In addition, the report combines PowerPoint analysis with an Excel-based forecast model for deeper market evaluation.

Key Insights in the Insomnia Therapeutics Market

The insomnia market across the 7MM was valued at $3.1 billion in 2022 and is projected to reach $3.8 billion by 2032, growing at a CAGR of 2.1%.

The report highlights:

  • Five late-stage pipeline products in Phase II and III development
  • The continued dominance of Z-drugs as first-line therapy
  • Forecast sales contribution of $288 million from two pipeline products by 2032
  • Evolving treatment patterns and competitive dynamics
  • Strategic implications of emerging therapies entering the market

The analysis also explores how pipeline innovation may influence future market share and treatment adoption.

Scope

What You Will Learn

The report provides detailed insights into:

  • Insomnia market forecasts from 2022–2032

  • Epidemiology, symptoms, diagnosis, and disease management

  • Treatment usage patterns and therapy costs

  • Pipeline products and mechanisms of action

  • Clinical trial activity and emerging trends

  • Competitive landscape and strategic positioning

  • Industry drivers, restraints, and challenges

Target Buyers for This Report

This report is designed for professionals across the pharmaceutical and healthcare sectors, including:

  • Pharmaceutical manufacturers

  • Business development and licensing teams

  • Commercial strategy teams

  • Investors and private equity firms

  • Market intelligence professionals

  • Healthcare consulting firms

If you are evaluating opportunities in sleep therapeutics or planning long-term strategy in the insomnia market, this report provides valuable market intelligence.

How Companies Use This Report

  • Pharmaceutical companies
    Evaluate pipeline opportunities and commercialization strategies

  • Business development teams
    Support licensing and partnership decisions

  • Investors and private equity firms
    Assess market growth and emerging players

  • Commercial and marketing teams
    Refine competitive positioning and launch strategies

  • Market intelligence professionals
    Track market evolution and treatment trends

As a result, organizations can make more informed strategic and investment decisions.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecasts includes the 7MM

Forecasts covers from 2022-2032

Reasons to Buy

Explore Pipeline Innovation and Competitive Intelligence

The report delivers detailed pipeline analysis focused on emerging therapies and mechanisms of action under development for insomnia.

It includes:

  • Clinical trial mapping

  • Late-stage pipeline profiling

  • Strategic competitor assessment

  • Market characterization and unmet needs analysis

  • Current and future competitive landscape evaluation

This enables users to identify high-potential opportunities and anticipate competitive shifts within the insomnia therapeutics market.

Built on Trusted Market Analysis and Forecasting

This report combines epidemiology, treatment data, market forecasting, and pipeline intelligence to provide a structured view of the insomnia therapeutics market.

Built using:

  • Forecast modeling across the 7MM

  • Clinical and pipeline analysis

  • Market characterization and competitor assessment

  • Treatment usage and cost-of-therapy data

  • Independent qualitative and quantitative research

Therefore, users gain a reliable framework for evaluating current and future market opportunities.

Act Now to Capture Emerging Opportunities in Sleep Therapeutics

The insomnia therapeutics market continues to evolve as new treatments and pipeline products reshape competitive dynamics.

This report helps you identify where growth opportunities are emerging, how treatment patterns are changing, and which companies are positioned to influence the future market landscape.

If you are planning investment, commercialization, or pipeline strategy in the insomnia market, now is the time to act.

Merck & Co Inc
Viatris Inc
Sumitomo Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Neurim Pharmaceuticals Ltd
Vanda Pharmaceuticals Inc
Sanofi
Taisho Pharmaceutical Holdings Co Ltd
Idorsia Pharmaceutical Ltd
EUSOL Biotech Co Ltd
Imbrium Therapeutics LP
Currax Holdings USA LLC

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

2.1. Summary of Updates

3. Disease Overview

3.1. Overview of Insomnia

3.2. Insomnia SWOT Analysis

3.3. Pathophysiology of Insomnia

3.4. Classification of Insomnia

4. Epidemiology

4.1. Total Prevalent Cases of Insomnia, Both Sexes, Ages ≥15 Years, 2022-32

4.2. Age-Specific Trends in the Total Prevalent Cases of Insomnia, Both Sexes, 2022

4.3. Sex-Specific Total Prevalent Cases of Insomnia, Both Sexes, Ages ≥15 Years, 2022

4.4. Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages ≥15 Years, 2022

4.5. Sex-Specific Total Prevalent Cases of Chronic Insomnia, Ages ≥15 Years, 2022

4.6. Sources and Methodology for Acute and Chronic Insomnia Prevalence

4.7. Sources and Methodology – Total Prevalent Cases of Acute and Chronic Insomnia

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: Benzodiazepines (e.g., estazolam, temazepam, flurazepam)

5.4. Product Profile: Z-Drugs (zaleplon, zolpidem, zopiclone, eszopiclone)

5.5. Product Profile: Melatonin Receptor Agonists (ramelteon and melatonin ER)

5.6. Product Profile: Low-Dose Antidepressants (doxepin, trazodone, trimipramine)

5.7. Product Profile: Antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine)

5.8. Product Profile: Gabapentinoids (e.g., gabapentin and pregabalin)

5.9. Product Profile: Merck & Co’s Belsomra (suvorexant)

5.10. Product Profile: Eisai’s Dayvigo (lemborexant)

5.11. Product Profile: Idorsia’s Quviviq (daridorexant)

5.12. Product Profile: Taisho Pharmaceutical’s Borzi (vornorexant)

5.13. Patient Flow: Insomnia in 2022 Across 7MM

6. Unmet Needs and Opportunities

6.1. Unmet Needs in Insomnia

6.2. New Therapeutic Options with Improved Efficacy

6.3. Improved Physician Awareness of Insomnia Treatments

6.4. Improved Patient Access to CBT-i

7. R&D Strategies

7.1. Trends in Clinical Trial Design in Insomnia

7.2. Trends in Deal-Making in Insomnia

8. Pipeline Assessment

8.1. Insomnia Pipeline Overview

8.2. Late-Stage Pipeline Agents for Insomnia

8.3. Product Profile: EUSOL Biotech’s SM-1

8.4. Product Profile: Imbrium Therapeutics’s Sunobinop

8.5. Product Profile: Vanda Pharmaceuticals’s Hetlioz (tasimelteon)

8.6. Insomnia: Clinical Trials (Phase II/III) Overview

9. Market Outlook

9.1. Insomnia Market Forecast

9.2. Market Drivers and Barriers

10. Appendix

10.1. Primary Research: KOL Information

10.2. Primary Research: High-Prescriber Survey Information

10.3. Bibliography

10.4. About the Authors

11. Contact Us

Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

Most Popular
$35,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Insomnia reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032 in real time.

  • Access a live Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more